scholarly journals Radiation-Associated Sarcoma of the Breast in a Patient With a Germline Tumor Protein p53 Mutation

Cureus ◽  
2021 ◽  
Author(s):  
Cheyenne Thompson ◽  
Muhammad O Hakim ◽  
Jorge Infante-Mendez ◽  
Susan Kesmodel ◽  
Neha Goel
2015 ◽  
Vol 11 (1) ◽  
pp. 699-704 ◽  
Author(s):  
YU WANG ◽  
YI-NI CHEN ◽  
WEI ZHANG ◽  
YU YANG ◽  
WEN-KUN BAI ◽  
...  

2008 ◽  
Vol 65 (11) ◽  
pp. 820-824
Author(s):  
Sladjana Zivkovic ◽  
Milos Kostov ◽  
Svetlana Pavlovic ◽  
Zaklina Mijovic

Background/Aim. Renal carcinoma represents histologically heterogeneous group of malignant tumors, with various clinical aggressiveness. The frequency of p53 mutation in primal renal carcinoma is rare, although there are information about its heterogeneous accumulation. The loss of protein p16 expression in primal renal carcinoma is detected in 20-30% of the cases. The aim of this paper was to determine frequency of mutated protein p53 and expression of protein p16INK4a in renal carcinoma, to analyze their correlative relation and relation with the examined clinicopathological parameters. Methods. The examination included 12 patients (66.7% men, 33.3% women), with patohistologically verified renal carcinoma. Expression of mutated form of protein p53 and protein p16 was determined in tissue samples, by immunohistochemical analysis using of mice monoclonical antibodies produced by DAKO, Denmark. Results. In 9 (75%) of the cases was detected mutated protein p53, of whom 66.6% had higher histological gradus of tumor (G3-4) and higher pathological stadium of the disease (pT3a-b) at the same time. In 7 (58.3%) and 5 (41.7%) of the cases expression of protein p16, the loss of expression of protein p16 were detected respectively. A statistically significant positive correlation was determined between pathological stadium of disease (TNM) and the degree of tumor differentiation (G) (? = 0.834; p < 0.001), as well as between TNM and mitotic index (? = 0.622; p = 0.031). Conclusion. A mutated form of protein p53 exists in 75% of the cases with the renal carcinoma and 66.6% of then have higher histological gradus of tumor and higher stadium of tumor disease at the same time. Coexpression of mutated protein p53 and protein p16INK4a in renal carcinoma is not statistically significant and it is not in correlation with clinicopathological parameters. Immunohistochemical analysis of mutated protein p53 in renal carcinoma can have predictive significance.


2013 ◽  
Vol 17 (1) ◽  
pp. 31-47 ◽  
Author(s):  
April D. Sorrell ◽  
Carin R. Espenschied ◽  
Julie O. Culver ◽  
Jeffrey N. Weitzel

2020 ◽  
Vol 14 (12) ◽  
pp. 1139-1150
Author(s):  
Chang-feng Guo ◽  
Yugang Zhuang ◽  
Yuanzhuo Chen ◽  
Sheng Chen ◽  
Hu Peng ◽  
...  

Aim: Tumor protein p53 ( TP53) mutant is one of the most frequently mutated genes in glioma. Results: The Cancer Genome Atlas data has shown that TP53 mutation is present in 49% of lower grade (World Health Organization [WHO] grades II and III) glioma patients. Data from The Genomics of Drug Sensitivity in Cancer database showed that three drugs: (5Z)-7-oxozeaenol, dabrafenib and nutlin-3a (−), have shown more resistance in patients with TP53 mutation. We identified 1100 differentially expressed genes. Functional enrichment analysis showed that the differentially expressed genes are mainly concentrated in the transport of ionic and cancer-related pathways. The top ten hub genes were identified and an outcome analysis revealed the most critical genes related to prognosis. Conclusion: Our results identified the key genes and pathways that might provide the basic proof to improve individualized treatment in patients with glioma.


2002 ◽  
Vol 97 (1-2) ◽  
pp. 140E-140E ◽  
Author(s):  
J. Nowak ◽  
R. Tomasini ◽  
M.-G. Mattei ◽  
L.A. Azizi Samir ◽  
J.-C. Dagorn ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document